Progenity Osake

Progenity EBITDA

Delisted

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Progenity (PROG) 15.8.2026 päivämäärällä on −166,00 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −195,19 M USD — muutos −14,95 % (korkeampi).

EBITDA

−166,00 MUSD

YoY

−14,95%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Progenity on 2026 −166,00 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Progenity oli 2025 −195,19 M USD. Se laskee −14,95% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Progenity Osakeanalyysi

Mitä Progenity tekee? Progenity Inc. is an American company specializing in the development and marketing of diagnostic tests and genetic screening solutions. It was founded in 2012 and is headquartered in San Diego, California. Progenity is a leading provider of prenatal screening and diagnostic solutions. The company offers a wide range of tests that help expectant parents identify potential health risks for their unborn child. Progenity's prenatal screening palette includes tests for determining chromosomal abnormalities, genetic disorders, and other health risks. A major advantage of these tests is that they are non-invasive, meaning that no dangerous invasive procedures need to be performed. Another important division of Progenity focuses on gastrointestinal health, where the company offers various diagnostic tests to identify and treat gastrointestinal diseases early. This includes tests for detecting colon cancer as well as genetic tests that indicate an increased risk for familial colon cancer syndromes. Progenity also has a division that focuses on cardiovascular diseases. Here, they offer genetic tests, among other things, to determine the risk of heart disease. In addition, the company offers a wide range of diagnostic solutions for general health, such as tests for identifying infectious diseases like HIV or HPV. Progenity also offers its customers various screening and diagnostic tests tailored to specific target groups. This includes tests for women seeking fertility treatment, as well as tests aiming to identify specific hereditary diseases related to cancer or other conditions. To provide customers with the best possible solutions, Progenity utilizes state-of-the-art technologies and innovative methods. The company is a leader in the application of liquid biopsy tests, an innovative method for identifying cancer cells in the blood. For a long time, Progenity has worked closely with leading US health authorities and is accredited by CLIA, the Clinical Laboratory Improvement Amendments. This means that the company operates in accordance with established standards and best practices and can provide its customers with accurate and reliable diagnostic solutions. In recent years, Progenity has experienced an impressive growth rate and has become a recognized provider of diagnostic solutions with a wide range of tests covering various areas of health. The company is committed to providing customers with the best possible solutions to promote their health and well-being. Progenity on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Progenity osakkeesta

Yhtiön Progenity EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −166,00 M USD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Progenity muuttui arvosta −195,19 M USD arvoon −166,00 M USD, mikä edustaa −14,95 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Progenity:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Progenity historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Progenity

Kaikki tunnusluvut — Progenity